Company: Strategy

From its inception ISA Pharmaceuticals has adopted a market driven strategy focused on the development of SLP® based therapies for unmet medical needs. This strategy has resulted in a portfolio of products under development with HPV-SLP® vaccine for the treatment of Vulvar Intraepithelial Neoplasia (VIN) as lead product. ISA's objective is to bring products to clinical proof-of-concept stage (phase II) after which it shall partner with industry players for subsequent development and commercialization.

ISA has developed a strong and efficient product development capability by combining its SLP® platform, clinical expertise and efficient access to small scale GMP manufacturing. One of the elements embedded in ISA's strategy is a consistent strive for efficiency. Limited overhead has resulted in an almost entire allocation of financial resources for research and clinical development, this being leveraged by strategic collaborations with international research groups and medical centers. In parallel, the company has been able to create an excellent intellectual property portfolio, thus ensuring the company's future value.